| Condition | Additional Trial Information |
| Anticoagulant Reversal | Efficacy and Safety Study of BERIPLEX® P/N Compared With Plasma in Patients on Anticoagulant Therapy Who Require Emergency Surgery or Invasive Intervention
> Learn More |
| Acute Major Bleeding: Blood Coagulation Disorders | Efficacy and Safety Study of BERIPLEX® P/N Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy
> Learn More |
Congenital Fibrinogen Deficiency
| Fibrinogen Concentrate (Human) − Efficacy and Safety Study
> Learn More |
Emphysema Caused by API Deficiency
| Study of Zemaira i.v. Administration in Subjects Who Completed a 2-Year Controlled Study With This Treatment and Have Emphysema Due to alpha1 -Proteinase Inhibitor Deficiency.
> Learn More |
| Emphysema Caused by API Deficiency | Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor (API) Deficiency
> Learn More |
Factor XIII Deficiency
| A Study of the Use of Factor XIII Concentrate in Patients with Inherited FXIII Deficiency
> Learn More |
| Factor XIII Deficiency | A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
> Learn More |
| Healthy | Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers
> Learn More |
| Hemophilia A | Study of a Plasma-Derived von Willebrand Factor/Factor VIII Concentrate (vWF/FVIII) , Biostate®, in Subjects with Hemophilia A
> Learn More |
| Hereditary Angioedema | C1 Esterase Inhibitor in HAE (Extension Study)
> Learn More |
| Primary Immune Deficiency | Safety Study of Subcutaneous Ig NextGen 16% in Patients With Primary Immunodeficiency
> Learn More |
| Von Willebrand Disease | Study of a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate (vWF/FVIII), Biostate®, in Subjects With Von Willebrand Disease
> Learn More |